EGFR and lung adenocarcinoma: Epidermal growth factor receptor (EGFR) mutations remains the most common driver mutations in patients with lung adenocarcinomas (LUAD), with an incidence of 50% in Asians and 9.8% in Caucasian Europeans (1, 2).